Abstract | BACKGROUND: METHODS: Acute STEMI patients who received thrombolytic therapy within first 12 h were included in our study. The PAI-1 4G/5G promoter region insertion/deletion polymorphism was studied from venous blood samples. Patients with the PAI-1 4G/5G gene polymorphism were included in group 1 and the others were included in group 2. Coronary angiography was performed in all patients in the first 24 h after receiving thrombolytic therapy. Thrombolysis in myocardial infarction (TIMI) 0-1 flow in the infarct-related artery was considered as 'no flow', TIMI 2 flow as 'slow flow', and TIMI 3 flow as 'normal flow'. RESULTS: A total of 61 patients were included in our study. Thirty patients (49.2%) were positive for the PAI-1 4G/5G gene polymorphism, whereas 31 of them (50.8%) were in the control group. There were significantly more patients with 'no flow' (14 vs. 6; P=0.02) and less patients with 'normal flow' (8 vs. 19; P=0.02) in group 1. In addition, time to thrombolytic therapy (TTT) was maximum in the 'no flow' group and minimum in the 'normal flow' group (P=0.005). In the logistic regression analysis, TTT (odds ratio: 0.9898; 95% confidence interval: 0.982-0.997; P=0.004) and the PAI-1 4G/5G gene polymorphism (odds ratio: 4.621; 95% confidence interval: 1.399-15.268; P<0.01) were found to be independently associated with post-thrombolytic 'no flow'. CONCLUSION: The PAI-1 4G/5G gene polymorphism and TTT are associated independently with 'no flow' after thrombolysis in patients with STEMI.
|
Authors | Bugra Ozkan, Caglar E Cagliyan, Zafer Elbasan, Onur K Uysal, Gulhan Y Kalkan, Mehmet Bozkurt, Kamuran Tekin, Sevcan T Bozdogan, Ozge Ozalp, Mustafa Duran, Durmus Y Sahin, Murat Cayli |
Journal | Coronary artery disease
(Coron Artery Dis)
Vol. 23
Issue 6
Pg. 400-3
(Sep 2012)
ISSN: 1473-5830 [Electronic] England |
PMID | 22850480
(Publication Type: Journal Article)
|
Chemical References |
- Fibrinolytic Agents
- Plasminogen Activator Inhibitor 1
- SERPINE1 protein, human
- Streptokinase
- Tissue Plasminogen Activator
|
Topics |
- Aged
- Coronary Angiography
- Coronary Vessels
(pathology)
- Female
- Fibrinolytic Agents
(therapeutic use)
- Gene Frequency
- Genotype
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy, genetics, pathology)
- Plasminogen Activator Inhibitor 1
(genetics)
- Polymorphism, Genetic
- Risk Factors
- Streptokinase
(therapeutic use)
- Thrombolytic Therapy
(methods)
- Tissue Plasminogen Activator
(therapeutic use)
- Treatment Outcome
|